A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic

Criteria

Inclusion criteria:

• Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection

• Willing to accept and consent for accepting hepatitis C positive graft

Exclusion criteria:

• Existing chronic liver disease (liver cirrhosis)

• Concomitant infection with HIV or Chronic hepatitis B

• Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection

• Pregnancy (Pregnant patients do not undergo solid organ transplants)